EL7.AI
StocksMediumUpdated•Originally published 25 June 2026•Updated 25 June 2026•
1 min read

DeepHealth Gets Two FDA Clearances for Breast AI with Cardiovascular Insight

Orange-toned illustration of DeepHealth AI medical imaging systems, FDA approval seals, and diagnostic data screens.

Key Facts

1DeepHealth received two FDA 510(k) clearances for new AI-powered Breast Suite functionalities: Breast Arterial Calcification Assessment and prior exam integration.

In a move that underscores AI's role in early diagnosis, DeepHealth, a subsidiary of RadNet (NASDAQ: RDNT), received two FDA 510(k) clearances for new AI-powered features in its Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior exam integration for image comparison, the company announced via GlobeNewswire.

The clearances come amid growing interest in AI for medical imaging. Adding BAC assessment could facilitate early detection of cardiovascular disease. Per market data, RDNT closed at $53.74 on June 18, 2026, after trading between $52.88 and $55.95. These approvals are expected to expand DeepHealth's product reach and potentially boost revenue for the parent company.

On the technical side, $52.88 acts as near-term support and $55.95 as resistance. Investors will watch RadNet's upcoming earnings to gauge the financial impact of these clearances, along with any further regulatory progress in AI imaging.